Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 28.5% in September

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 71,900 shares, a drop of 28.5% from the August 31st total of 100,500 shares. Currently, 4.6% of the company’s shares are sold short. Based on an average daily trading volume, of 136,800 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 136,800 shares, the short-interest ratio is presently 0.5 days. Currently, 4.6% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Alaunos Therapeutics Stock Up 23.3%

NASDAQ:TCRT opened at $3.70 on Thursday. Alaunos Therapeutics has a 12-month low of $1.31 and a 12-month high of $6.20. The firm has a market capitalization of $8.16 million, a P/E ratio of -1.50 and a beta of -0.84. The stock’s fifty day simple moving average is $2.42 and its 200-day simple moving average is $2.87.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.33) by $4.70.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.